Sign In
Last checked at 
8 Jun 2018 11:50
Hikma Pharmaceuticals PLC - EIP Awards
LONDON, 8 June 2018: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK)(LEI: 549300BNS685UXH4JI75) announces that the Remuneration Committee has made the following nil cost option under the Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan (the "EIP") to a Person Discharging Managerial Responsibility ("PDMR") of the Company.
The Award under the EIP was made on 7 June 2018 at a price of 1,035 pence per Ordinary Share (being the average price for the 30-day period prior to 31 December 2017, in accordance with the EIP rules) as follows:
Notification and public disclosure of transactions by persons discharging managerial responsibilities
Surendera Tyagi
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Surendera Tyagi |
2 | Reason for the notification | |
a) | Position/status | Chief Scientific Officer and Global Head of R&D |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction
| The Company granted the named individual above a nil-cost option award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years, subject to continued employment. |
c) | Price(s) and volume(s) | Price(s): £10.35 Volume(s): 28,818 |
d) | Aggregated information | N/A |
e) | Date of the transaction | 7 June 2018 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Peter SpeirsCompany Secretary, responsible for releasing this announcement+44 (0) 20 7399 2760
Follow the stocks
